Pfizer China announced that the National Medical Products Administration (NMPA) has officially approved the new-generation ...

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

SHANGHAI, March 6 () - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management ‌in overweight ...

China's National Medical Products Administration has approved Pfizer Inc.’s PFE ecnoglutide injection for chronic weight ...

Troubled by a pain in her ear, Kerry Sharples from Crewe, Cheshire, saw her doctor - the mum had no idea of the devastating ...

Shanghai: China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese ...

China has approved Pfizer's GLP-1 drug Xianweiying for long-term weight management in overweight or obese adults, the U.S.

Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new--generation ...

Pfizer has partnered with Sciwind Biosciences for a new type 2 diabetes drug. The deal could be worth up to 495 million ...

The stock is down, but the good news is that it sports a fat dividend yield of 6.4%. Pfizer has been struggling lately, but ...

Agreement worth up to $495 million is part of a growing number of Chinese deals with global pharma giants as the country ...

Chennai: Caplin Steriles Limited, a wholly owned subsidiary of Caplin Point Laboratories Limited, has received final approval ...